pan-caspase inhibitors (Aurigene)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namepan-caspase inhibitors (Aurigene)
Drug Alias Nameapoptosis inhibitors (Aurigene)AU-258AU-260AU-259
ClassificationSmall molecules
Mechanisms of ActionApoptosis inhibitorsNeuroprotectantsCaspase inhibitors
TargetsCaspase
Therapy Area/IndicationsNerve DegenerationMyocardial InfarctionStroke
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAurigene Oncology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAurigene Oncology Ltd
Active IndicationsN/A
Inactive IndicationsNerve DegenerationMyocardial InfarctionStroke

Other Information

ATC CodeN/A
Related LinksN/A